📰 Breaking News: Lessons Learnt & Insights from DSTBTD Restructuring Plan

Verso Biosense R&D Limited

Active Company no. 09890252 Incorporated Nov 2015 Financial Services EC postcode area

Companies House record →

6th Floor 2 London Wall Place, London, EC2Y 5AU

The most recent insolvency notice for Verso Biosense R&D Limited is a Notices to creditors (MVL), published 28 September 2026 in The London Gazette. The office holders are Nicola Kate Clark (IP No. 19390) of MHA Advisory Limited, 80 Mosley Street, Manchester, M2 3FX; Andrew John Duncan (IP No. 9319) of MHA Advisory Limited, 6th Fl. Its last accounts filed at Companies House, to 31 December 2024, showed total assets of £80 and net assets of -£11k. A members' voluntary liquidation (MVL) is the solvent, orderly winding-up of a company that can pay its debts in full — usually part of a director's retirement, a group restructure, or closing a company that has served its purpose. It is a planned closure, not a sign of financial distress.

Last filed balance sheet

As at 31 December 2024 · total exemption full accounts · unaudited · filed 21 months before the first insolvency notice

Total assets
£80
Cash at bank
£70
Net assets
-£11k
Total liabilities
£11k

Insolvency notices (3)

  1. The notice informs creditors of VERSO BIOSENSE R&D LIMITED that a final distribution will be made after its voluntary winding up and sets a deadline to submit claims.

  2. Verso Biosense R&D Limited has appointed two liquidators, Nicola Kate Clark and Andrew John Duncan, on 23 September 2026 in a members' liquidation.

  3. The notice announces that VERSO BIOSENSE R&D LIMITED resolved to be voluntarily wound up and appointed Nicola Kate Clark and Andrew John Duncan as joint liquidators at a general meeting on 23 September 2026.

Owed money by Verso Biosense R&D Limited?

A bad debt this size rarely stops with the company that failed. If you're a supplier or creditor left short, it's worth knowing where you rank — and checking what the shortfall does to your own cashflow.

What to do when a customer fails

Related guidance

Frequently asked questions

Is Verso Biosense R&D Limited in financial difficulty?

No — the most recent process is a solvent one. A members' voluntary liquidation (MVL) is the solvent, orderly winding-up of a company that can pay its debts in full — usually part of a director's retirement, a group restructure, or closing a company that has served its purpose. It is a planned closure, not a sign of financial distress. The most recent insolvency notice for Verso Biosense R&D Limited (company no. 09890252) is a Notices to creditors (MVL), published 28 September 2026 in The London Gazette.

What were Verso Biosense R&D Limited's last filed accounts?

Verso Biosense R&D Limited's last accounts filed at Companies House, to 31 December 2024, showed total assets of £80, cash of £70, net assets of -£11k. For a distressed company the last filing often predates the insolvency by a year or more.

How many insolvency notices does Verso Biosense R&D Limited have?

Verso Biosense R&D Limited has 3 insolvency notices recorded in The London Gazette, the most recent being a Notices to creditors (MVL) on 28 September 2026.

Financial figures are taken from the company's own last accounts filed at Companies House. Small and micro-entity accounts are unaudited, and for a company entering an insolvency process the most recent filing frequently predates that process by a year or more. Figures are indicative and are not a valuation. Contains public sector information licensed under the Open Government Licence v3.0. © Crown copyright.